| Name | Title | Contact Details |
|---|
For over 25 years, Guaranteed Returns has provided pharmaceutical return services to hospital, government, independent retail, chain-store, LTC, Mail-Order and clinic pharmacies. Local GRx on-site service representatives are highly valued by customers for their professionalism, trustworthiness and for “going above and beyond”. Guaranteed Returns puts their longevity and industry knowledge to work to obtain the maximum amount of credits for every pharmacy return. GRx concentrates on providing pharmaceutical return solutions that address all aspects of the business, beginning with the manufacturer, through crediting the customer. Business review consultations, inventory management assistance and an unbeatable customer service department are just a few of the attributes that customers say sets GRx apart. Their flagship program, ReverseLink One™ has been branded as “the most cost effective return goods program ever to be offered by any 3rd party returns company”. Guaranteed Returns is dedicated to making pharmaceutical returns as simple as possible for customers while attaining the maximum amount of credits. Guaranteed Returns puts their 25 years of knowledge to work every day – continually investing in new programs, technologies and people - which is why GRx delivers Service You Can Count On.
HCSC is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Neich Medical Co. is a Dublin, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Mena Regional Health System is a Mena, AR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kite Pharma, founded in 2009, is dedicated to the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to fight tumor cells. Kite’s lead programs are in collaboration with the National Cancer Institute (NCI) and are being studied through the NCI’s Surgery Branch led by Steven A. Rosenberg, MD, PhD, who has pioneered immunotherapy approaches for cancer for more than two decades. This research has resulted in breakthrough clinical findings, including results from an NCI Phase 1/2a trial being presented at this year’s American Society of Hematology (ASH) Annual Meeting. Based on this progress and momentum, Kite plans to initiate a company-sponsored multicenter clinical program in aggressive non-Hodgkin’s lymphoma, with additional filings expected for other eACT™ products in diverse oncology indications.